Time & Date: 2 September, 16:30 – 17:30 CEST
Chairpersons: S. Rizzo ITALY & C. Delcourt FRANCE
Speakers & Presentations:
S. Rizzo ITALY
16:30 Welcome
R. Guymer AUSTRALIA
16:32 HONU: a multicenter, prospective, observational study of the progression of intermediate age-related macular degeneration
M. Pfau GERMANY
17:38 Impact of the Complement C3 Inhibitor Pegcetacoplan on Photoreceptor Degeneration beyond Areas of Geographic Atrophy
Y. Lechanteur THE NETHERLANDS
16:44 Early-Onset Drusen Maculopathy is associated with rare genetic variants in the complement factor H gene and an early onset of endstage disease.
D. Barthelmes SWITZERLAND
16:50 Artificial Intelligence-Quantified Macular Fluid Volumes Impact 12 and 48 Month Treatment Outcomes in Eyes with Neovascular Age-Related Macular Degeneration – Data from the Fight Retinal Blindness! Project Zurich
Hr. Bogunovic AUSTRIA
16:56 Deep learning-based automated fluid monitoring from real-world management of neovascular AMD over five years
K. Teo SINGAPORE
17:02 Association between retinal thickness variation and visual acuity change in neovascular age-related macular degeneration
S. Rizzo ITALY
17:08 Archway Phase 3 Trial of the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration: End-of-Study Results
M. Becker SWITERLAND
17:14 Key Surgical Pearls for Best Practice During the Port Delivery System With Ranibizumab (PDS) Implant Insertion Procedure
All Faculty
17:20 Discussion
